Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial Meeting Abstract


Authors: Motzer, R. J.; de la Motte Rouge, T.; Harzstark, A. L.; Michaelson, M. D.; Liu, G.; Gruenwald, V.; Ingrosso, A.; Tortorici, M. A.; Bycott, P. W.; Kim, S.; Rini, B. I.
Abstract Title: Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880300588
PROVIDER: wos
DOI: 10.1200/jco.2011.29.15_suppl.4547
Notes: Meeting Abstract: 4547 -- Source: Wos
Altmetric Score
MSK Authors
  1. Robert Motzer
    769 Motzer